Tumor necrosis factor 6α and 6β

Details Tumor necrosis factor 6α and 6β Tumor necrosis factor 6α and 6β

2007-03-06

2007-03-06

O'Hara, Eileen B. (Department: 1646)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C530S387300, C530S402000, C424S185100, C424S192100, C424S450000, C536S023400, C536S023500

Reexamination Certificate

active

09518931

ABSTRACT:
The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6α & -6β proteins. TNFR-6α & -6β polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TNFR-6α & -6β activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.

REFERENCES:
patent: 4847325 (1989-07-01), Shadle et al.
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5620889 (1997-04-01), Lynch et al.
patent: 5632994 (1997-05-01), Reed et al.
patent: 5652210 (1997-07-01), Barr et al.
patent: 5663070 (1997-09-01), Barr et al.
patent: 5741667 (1998-04-01), Goeddel et al.
patent: 5830469 (1998-11-01), Lynch et al.
patent: 5874546 (1999-02-01), Nagata et al.
patent: 5885800 (1999-03-01), Emery et al.
patent: 5985614 (1999-11-01), Rosen et al.
patent: 6297367 (2001-10-01), Tribouley
patent: 6764679 (2004-07-01), Ashkenazi et al.
patent: WO95/33051 (1995-12-01), None
patent: WO96/34095 (1996-10-01), None
patent: WO98/30694 (1998-07-01), None
patent: 0 861 850 (1998-09-01), None
patent: WO99/26977 (1998-11-01), None
patent: WO98/56892 (1998-12-01), None
patent: WO99/04001 (1999-01-01), None
patent: WO99/07738 (1999-02-01), None
patent: WO99/11791 (1999-03-01), None
patent: WO99/14330 (1999-03-01), None
patent: WO99/31128 (1999-06-01), None
patent: WO99/33980 (1999-07-01), None
patent: WO99/46376 (1999-09-01), None
patent: WO99/50413 (1999-10-01), None
patent: WO00/01817 (2000-01-01), None
patent: WO00/32221 (2000-06-01), None
patent: WO00/34782 (2000-06-01), None
patent: WO00/37094 (2000-06-01), None
patent: WO00/46247 (2000-08-01), None
patent: WO00/52028 (2000-09-01), None
patent: WO00/53223 (2000-09-01), None
patent: WO00/53755 (2000-09-01), None
patent: WO00/53758 (2000-09-01), None
patent: WO00/58465 (2000-10-01), None
patent: WO00/58466 (2000-10-01), None
patent: WO00/60079 (2000-10-01), None
patent: WO01/22920 (2001-04-01), None
patent: WO01/28582 (2001-04-01), None
patent: WO01/42434 (2001-06-01), None
patent: WO01/42463 (2001-06-01), None
patent: WO01/68912 (2001-09-01), None
patent: WO02/00677 (2002-01-01), None
patent: WO02/000928 (2002-01-01), None
patent: WO02/09668 (2002-02-01), None
patent: WO02/060317 (2002-08-01), None
patent: WO02/060947 (2002-08-01), None
patent: WO02/060949 (2002-08-01), None
patent: WO02/078524 (2002-10-01), None
Skolnick, J. and J. S. Fetrow, “From genes to protein structure and function: novel applications of computational approaches in the genomic era”, Trends in Biotech, 18(1):34-39, 2000.
Vukicevic et al., 1996, PNAS USA 93:9021-9026.
Genbank Accession No. AA025673 (Aug. 16, 1996).
Kwon et al.,The Journal of Biological Chemistry, 272:14272-14276 (1997).
GenBank Accession No. W67560 (Oct. 16, 1996).
GenBank Accession No. M91489 (Oct. 29, 1992).
Gieser et al.,Genomics, 13(3):873-876 (Jul. 1992).
Hiller et al.,Genome Research, 6:807-828 (1996).
Pitti et al.,Nature, 396:699-703 (Dec. 17, 1998).
Kikuno et al., “Prediction of the Coding Sequences of Unidentified Human Genes, XIV, the Complete Sequences of 100 New cDNA Clones from Brain Which Code for Large Proteinsin vitro,” DNA Research 6: 197-205 (1999).
Bai et al., “Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster,” PNAS 97(3):1230-1235 (Feb. 1, 2000).
Yu et al., “A Newly Identified Member of Tumor Necrosis Factor Receptor Superfamily (TR6) Suppresses LIGHT-mediated Apoptosis,” The Journal of Biological Chemistry 274(20):13733-13736 (May 14, 1999).
Rabinowich et al., “Lymphocyte Apoptosis Induced by Fas Ligand-expressing Ovarian Carcinoma Cells,” J. Clin. Invest. 101(11):2579-2588 (Jun. 1998).
Walker et al., “Tumor expression of Fas ligand (CD95L) and the consequences,” Current Opinion in Immunology 10:564-572 (1998).
Gratas, et al., “Up-Regulation of Fas (APO-1/CD95) Ligand and Down-Regulation of Fas Expression in Human Esophageal Cancer,” Cancer Research 58:2057-2062 (May 15, 1998).
Buzyn et al., “Membrane-Bound Fas (Apo-1/CD95) Ligand on Leukemic Cells: A Mechanism of Tumor Immune Escape in Leukemia Patients,” Blood 94(9):3135-3140 (Nov. 1, 1999).
Zhang et al., (Jun. 2001). Modulation of T-cell Responses to Alloantigens by TR6/DcR3.The Journal of Clinical Investigation107(11) : 1459-1468.
Connolly et al., (2001). In Vivo Inhibition of Fas-Ligand-Mediated Killing by TR6, a Fas Ligand Decoy Receptor.The Journal of Pharmacology and Experimental Therapeutics298(1): 25-33.
Duesterhoeft et al., Genbank Accession No. AL157435, Feb. 15, 2000.
U.S. Appl. No. 09/912,293, Rosen et al.
Yu et al., GenBank Accession No. AF 134240, May 11, 1999.
Ashkenazi and Dixit, “Apoptosis control by death and decoy receptors,” Curr. Opin. Cell Biol. 11 (2), 255-260 (1999).
Kikuno et al., PIR Accession No. T45294, Jan. 31, 2000.
Bai et al., GenBank Accession No. AF217793, Feb. 12, 2000.
Bai et al., GenBank Accession No. AF217794, Feb. 12, 2000.
Bai et al., GenBank Accession No. AF217796, Feb. 21, 2000.
Yan et al., “Two-Amino Acid Molecular Switch in an Epithelial Morphogen. . . ,” Science 290, 523-527, (Oct. 20, 2000).
Ohshima et al., “Amplification and expression of a decoy receptor for Fas ligand. . . ,” Cancer Letters 160, 89-97, (2000).
Locksley et al., “The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology,” Cell 104, 487-501, (Feb. 23, 2001).
Wallis, GenBank Accession No. AL353715, Apr. 18, 2001.
Matthews, GenBank Accession No. AL121845, Jul. 6, 2001.
Pitti et al., GenBank Accession No. NM 032945, Jul. 6, 2001.
Pitti et al., GenBank Accession No. NM 032957, Jul. 17, 2001.
Adams et al., “Initial assessment of human gene diversity and expression patterns,” Nature 377 (6547 Supp) 3-174, (Sep. 28, 1995).
Adams et al., Genbank Accession No. AA325843, Apr. 20, 1997.
Hillier et al., GenBank Accession No. AA025672, Feb. 1, 1997.
Hillier et al., GenBank Accession No. AA155646, Nov. 8, 1997.
Badley et al., “Upregulation of Fas Ligand Expression by Human Immunodeficiency Virus in Human Macrophages Mediates Apoptosis of Uninfected T Lymphocytes,”J. Virol., 70(1):199-206 (Jan. 1996).
Gruss et al., “Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas,”Blood, 85(12):3378-3404 (Jun. 15, 1995).
Matute-Bello et al., “Blockade of the Fas/FasL System Improves Pneumococcal Clearance from the Lungs without Preventing Dissemimnation of Bacteria to the Spleen,”J. Infect. Dis., 191:596-606 (Feb. 15, 2005).
Sung et al., “Transgenic Expression of Decoy Receptor 3 Protects Islets from Spontaneous and Chemical-induced Autoimmune Destruction in Nonobese Diabetic Mice,”J. Exp. Med., 199(8):1143-1151 (Apr. 19, 2004).

Affiliated with

Also associated with

Rating

Tumor necrosis factor 6α and 6β does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor necrosis factor 6α and 6β, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor necrosis factor 6α and 6β will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3728454